frontiers in Pharmacology

ERRATUM
published: 06 June 2016
doi: 10.3389/fphar.2016.00165

Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach

Frontiers Production Office *

Frontiers Production Office, Frontiers, Lausanne, Switzerland

OPEN ACCESS

Approved by:
Pharmacology Editorial Office, Frontiers, Switzerland

***Correspondence:**
Frontiers Production Office
production.office@frontiersin.org

Specialty section:
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

Received: *01 June 2016*
Accepted: *01 June 2016*
Published: *06 June 2016*

Citation:
Frontiers Production Office (2016) Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front. Pharmacol. 7:165. doi: 10.3389/fphar.2016.00165

Keywords: ranibizumab, bevacizumab, aflibercept, diabetic retinopathy, molecular dynamics

An erratum on

Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
by Platania, C. B. M., Di Paola, L., Leggio, G. M, Romano, G. L., Drago, F., Salomone, S., et al. (2015) Front. Pharmacol. 6:248. doi: 10.3389/fphar.2015.00248

Reason for Erratum:
Due to a typesetting error, the article was published with incorrect values in **Table 4** . The publisher apologizes for this error and the correct version of **Table 4** appears below. This error does not change the scientific conclusions of the article in any way.

REFERENCES

Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., et al. (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. *Angiogenesis* 15, 171–185. doi: 10.1007/s10456-011-9249-6

TABLE 4 | MM-PBSA results compared to experimental binding parameters.

Complex	Binding parameters			MM-PBSA energy terms (KJ/mol)				
	$K_{on}/10^5$ (M^{-1} s^{-1})	$K_{off}/10^{-5}$ (s^{-1})	K_D (pM)	$\Delta E_{binding}$	ΔE_{VdW}	$\Delta E_{electrostatic}$	ΔG_{Polar}	ΔG_{Apolar}
Ranibizumab/VEGFA	1.60	0.73	46	−760 ± 40	−418 ± 5	−160 ± 20	410 ± 30	−592 ± 7
Fab-bevacizumab/VEGFA	5.30	3.10	58	−807 ± 30	−362 ± 10	−252 ± 20	343 ± 30	−536 ± 7
VEGFR1d2_R2d3/VEGFA	410	2.01	0.49	−1440 ± 90	−307 ± 50	−1433 ± 100	1050 ± 100	−750 ± 40

Kinetic and binding parameters are from Papadopoulos et al. (2012).